BIIB

Biogen
D

BIIB

158.305
USD
2.39
(1.53%)
Market Open
Volume
52,171
EPS
14
Div Yield
-
P/E
20
Market Cap
23,071,347,476
Related Instruments
    ABBV
    ABBV
    -4.630
    (-2.73%)
    171.89 USD
    AMGN
    AMGN
    -12.22
    (-4.13%)
    289.74 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    SNY
    SNY
    0.160
    (0.33%)
    47.94 USD
    TAK
    TAK
    0.060
    (0.44%)
    13.625 USD
    More
News

Title: Biogen

Sector: Healthcare
Industry: Drug Manufacturers - General
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.